Callan Capital Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schwab International Equity ETF
SCHF
|
+$5.67M |
| 2 |
Schwab Fundamental US Large Company Index ETF
FNDX
|
+$5.59M |
| 3 |
JPMorgan Ultra-Short Municipal Income ETF
JMST
|
+$2.66M |
| 4 |
iShares International Equity Factor ETF
INTF
|
+$2.51M |
| 5 |
Vanguard Morningstar Mid-Cap ETF
VO
|
+$1.85M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Ultra-Short Income ETF
JPST
|
+$859K |
| 2 |
Invesco FTSE RAFI US 1000 ETF
PRF
|
+$752K |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$322K |
| 4 |
Vanguard FTSE All-World ex-US ETF
VEU
|
+$299K |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$230K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 93.45% |
| 2 | Technology | 3.27% |
| 3 | Consumer Discretionary | 0.87% |
| 4 | Communication Services | 0.83% |
| 5 | Financials | 0.47% |
Similar funds
Callan Capital's Q4 2021 Portfolio in Review
As of Q4 2021, Callan Capital held 134 positions worth $688M, up 14% from $602M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Callan Capital deployed $50.5M of net new capital in Q4 2021, opening 47 new positions and adding to 52 existing holdings. Its largest new stake was State Street SPDR Portfolio Developed World ex-US ETF: 37,340 shares worth $1.36M.
By sector, the portfolio is most concentrated in Miscellaneous at 93% of assets, down from 95% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was JPMorgan Ultra-Short Income ETF, an estimated $859K trimmed.
- Callan Capital's largest Q4 2021 buy was State Street SPDR Portfolio Developed World ex-US ETF: 37,340 shares worth $1.36M.
- Callan Capital added most to Schwab International Equity ETF in Q4 2021, an estimated $5.67M increase.
- Callan Capital's biggest Q4 2021 reduction was JPMorgan Ultra-Short Income ETF, cutting an estimated $859K.
- Callan Capital fully exited Evofem Biosciences, Inc. Common Stock in Q4 2021, selling an estimated $37K.
- Callan Capital's ten largest holdings make up 65% of its $688M portfolio in Q4 2021.
- Callan Capital opened 47 new positions and closed 1 in Q4 2021.
- Callan Capital's portfolio value rose 14% quarter-over-quarter to $688M.
Based on Callan Capital's 13F filing for Q4 2021, filed 21 Jan 2022.